Qiagen Sciences LLC therascreen EGFR RGQ PCR Kit (24), Reference Number REF 870121 Recall
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
therascreen EGFR RGQ PCR Kit (24), Reference Number REF 870121
Brand
Qiagen Sciences LLC
Lot Codes / Batch Numbers
All lots
Products Sold
All lots
Qiagen Sciences LLC is recalling therascreen EGFR RGQ PCR Kit (24), Reference Number REF 870121 due to There is a risk for a false mutation positive result in rare cases resulting from a fluorescence artefact. In these rare cases, the controls pass corr. Based on FDA medical device recall database.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
There is a risk for a false mutation positive result in rare cases resulting from a fluorescence artefact. In these rare cases, the controls pass correctly, while a fluorescence artefact in the mutation assay causes an incorrect valid mutation positive result.
Recommended Action
Per FDA guidance
Urgent Medical Device Correction notification letters dated 4/8/20 were sent to customers. Actions to be taken by the customer: For continued use of the therascreen EGFR RGQ PCR Kit (24), check the delta CT values (CT) in the sample result table for automated interpretation of results. For mutation positive results with a CT below -10.00, these should be considered invalid and retested. To implement the new cutoff for the delta CT (CT), the following new instruction replaces the Table 12 (p.46) of the therascreen EGFR RGQ PCR Kit Handbook. If you have concerns about previously generated mutation positive results with the therascreen EGFR RGQ PCR Kit (24), REF. 870121, the criteria listed above can be used for review. The mixing step described in the DNA sample assessment protocol (page 25, step 8) of the therascreen EGFR RGQ PCR Handbook dated October 2019 should also be performed after step 10 on page 36 of the mutation detection protocol. To obtain a valid qPCR result for the controls and samples, strict attention must be paid to thorough reagent mixing at each mixing step during the assay setup in accordance to the instructions for use. Forward this information to all individuals and departments within your organization who are using the therascreen EGFR RGQ PCR Kit (24), REF. 870121. If you are not the end user, please forward this notice to the product end user. Review this notice with your laboratory/medical director. Complete the Acknowledgement of Receipt form attached to this letter by April 24, 2020 and email it to quality.communications@qiagen.com. If you have any questions or concerns, please contact your local QIAGEN Technical Service Department through any of the following: Telephone: 800 362 7737 Email: TechService-NA@qiagen.com Actions taken by QIAGEN QIAGEN is revising the instructions for use as described in this notice to reduce any risk resulting from fluorescence artefacts leading to invalid runs or fals
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 10, 2026